Short answer
Aurinia Pharmaceuticals Inc. (AUPH) filed an 8-K current report with the SEC on April 3, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Aurinia to acquire Kezar for $6.955 cash plus one CVR per share, implying substantial near-term transaction certainty for Kezar holders.
Aurinia Pharmaceuticals Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Aurinia to acquire Kezar for $6.955 cash plus one CVR per share, implying substantial near-term transaction certainty for Kezar holders
- Offer launch required by April 13, 2026; 20-business-day tender period and expected second-quarter 2026 closing
- Closing requires majority tender participation and Kezar closing net cash of at least $50.0 million, with no financing condition
- CVRs provide potential upside from excess cash, partnered assets, Legacy Assets, milestones up to $88.0 million, and 3% royalties
- Tang Capital support covers approximately 9.0% of shares, strengthening tender-offer execution; $1.2 million termination fee applies in specified circumstances
Item 7.01 · Regulation FD Disclosure
- Aurinia and Parent announced execution of a merger agreement on March 30, 2026
- Merger terms and transaction implications are contained in Exhibit 99.1
- Announcement signals a potentially material ownership and strategic change for Aurinia shareholders
Item EX-99.1 · Exhibit EX-99.1
- Aurinia to acquire Kezar for $6.955 cash per share plus one contingent value right
- CVR provides potential participation in zetomipzomib proceeds, collaboration payments, asset-sale proceeds and excess closing net cash
- Zetomipzomib expands Aurinia’s autoimmune pipeline into autoimmune hepatitis, lupus nephritis and systemic lupus erythematosus
- Tender offer expected by April 13, 2026, with closing targeted for second quarter 2026
- Tang Capital’s 9.0% stake is committed to the transaction, supporting the majority-tender condition
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aurinia Pharmaceuticals Inc. 8-K filings
Get the next AUPH 8-K as it lands
Follow AUPH for push alerts, or ask the research agent what this filing means.